WEKO3
アイテム
{"_buckets": {"deposit": "d94e07bb-524d-4fd3-8634-ad5021c84524"}, "_deposit": {"created_by": 2, "id": "14015", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "14015"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00014015", "sets": ["11"]}, "author_link": ["50226", "50237", "50230", "50224", "50228", "50227", "50232", "50225", "50238", "50236", "50231", "50234", "50233", "50235", "50239", "50229"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "89", "bibliographicPageStart": "81", "bibliographicVolumeNumber": "94", "bibliographic_titles": [{"bibliographic_title": "International Journal of Hematology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The percentage of myeloperoxidase (MPO)-positive blast cells is a simple and highly significant prognostic factor in AML patients. It has been reported that the high MPO group (MPO-H), in which \u003e50% of blasts are MPO activity positive, is associated with favorable karyotypes, while the low MPO group (≤50% of blasts are MPO activity positive, MPO-L) is associated with adverse karyotypes. The MPO-H group shows better survival even when restricted to patients belonging to the intermediate chromosomal risk group or those with a normal karyotype. It has recently been shown that genotypes defined by the mutational status of NPM1, FLT3, and CEBPA are associated with treatment outcome in patients with cytogenetically normal AML. In this study, we aimed to evaluate the relationship between MPO positivity and gene mutations found in normal karyotypes. Sixty AML patients with normal karyotypes were included in this study. Blast cell MPO positivity was assessed in bone marrow smears stained for MPO. Associated genetic lesions (the NPM1, FLT3-ITD, and CEBPA mutations) were studied using nucleotide sequencing. Thirty-two patients were in the MPO-L group, and 28 patients in the MPO-H group. FLT3-ITD was found in 11 patients (18.3%), NPM1 mutations were found in 19 patients (31.7%), and CEBPA mutations were found in 11 patients (18.3%). In patients with CEBPA mutations, the carrying two simultaneous mutations (CEBPA (double-mut)) was associated with high MPO expression, while the mutant NPM1 without FLT3-ITD genotype was not associated with MPO activity. Both higher MPO expression and the CEBPA (double-mut) genotype appeared to be associated with improved overall survival after intensive chemotherapy. Further studies are required to determine the importance of blast MPO activity as a prognostic factor, especially in CEBPA wild-type patients with a normal karyotype.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "International Journal of Hematology, 94(1), pp.81-89: 2011", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Japanese Society of Hematology"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "21674360", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s12185-011-0883-y", "subitem_relation_type_select": "DOI"}}]}, "item_2_relation_42": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "http://hdl.handle.net/10069/30683"}]}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Japanese Society of Hematology 2011"}, {"subitem_rights": "The original publication is available at www.springerlink.com"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10797094", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09255710", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "18653774", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "日本血液学会"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Tominaga-Sato, Shinya"}], "nameIdentifiers": [{"nameIdentifier": "50224", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsushima, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "50225", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ando, Koji"}], "nameIdentifiers": [{"nameIdentifier": "50226", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Itonaga, Hidehiro"}], "nameIdentifiers": [{"nameIdentifier": "50227", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imaizumi, Yoshitaka"}], "nameIdentifiers": [{"nameIdentifier": "50228", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imanishi, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "50229", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwanaga, Masako"}], "nameIdentifiers": [{"nameIdentifier": "50230", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taguchi, Jun"}], "nameIdentifiers": [{"nameIdentifier": "50231", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukushima, Takuya"}], "nameIdentifiers": [{"nameIdentifier": "50232", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida, Shinichiro"}], "nameIdentifiers": [{"nameIdentifier": "50233", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hata, Tomoko"}], "nameIdentifiers": [{"nameIdentifier": "50234", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Moriuchi, Yukiyoshi"}], "nameIdentifiers": [{"nameIdentifier": "50235", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuriyama, Kazutaka"}], "nameIdentifiers": [{"nameIdentifier": "50236", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mano, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "50237", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomonaga, Masao"}], "nameIdentifiers": [{"nameIdentifier": "50238", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Yasushi"}], "nameIdentifiers": [{"nameIdentifier": "50239", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "IJH94_81.pdf", "filesize": [{"value": "211.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 211600.0, "url": {"label": "IJH94_81.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/14015/files/IJH94_81.pdf"}, "version_id": "98452107-ec40-4736-ac66-4f985e4639e1"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Acute myeloid leukemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CEBPA mutations", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Myeloperoxidase", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Normal karyotype", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts."}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/27422", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-08-01"}, "publish_date": "2012-08-01", "publish_status": "0", "recid": "14015", "relation": {}, "relation_version_is_last": true, "title": ["Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts."], "weko_shared_id": -1}
Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.
http://hdl.handle.net/10069/27422
http://hdl.handle.net/10069/274225f4002dd-3c69-4150-9045-3bc9b4cc5dbe
名前 / ファイル | ライセンス | アクション |
---|---|---|
IJH94_81.pdf (211.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-08-01 | |||||
タイトル | ||||||
タイトル | Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Acute myeloid leukemia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | CEBPA mutations | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Myeloperoxidase | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Normal karyotype | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Tominaga-Sato, Shinya
× Tominaga-Sato, Shinya× Tsushima, Hideki× Ando, Koji× Itonaga, Hidehiro× Imaizumi, Yoshitaka× Imanishi, Daisuke× Iwanaga, Masako× Taguchi, Jun× Fukushima, Takuya× Yoshida, Shinichiro× Hata, Tomoko× Moriuchi, Yukiyoshi× Kuriyama, Kazutaka× Mano, Hiroyuki× Tomonaga, Masao× Miyazaki, Yasushi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The percentage of myeloperoxidase (MPO)-positive blast cells is a simple and highly significant prognostic factor in AML patients. It has been reported that the high MPO group (MPO-H), in which >50% of blasts are MPO activity positive, is associated with favorable karyotypes, while the low MPO group (≤50% of blasts are MPO activity positive, MPO-L) is associated with adverse karyotypes. The MPO-H group shows better survival even when restricted to patients belonging to the intermediate chromosomal risk group or those with a normal karyotype. It has recently been shown that genotypes defined by the mutational status of NPM1, FLT3, and CEBPA are associated with treatment outcome in patients with cytogenetically normal AML. In this study, we aimed to evaluate the relationship between MPO positivity and gene mutations found in normal karyotypes. Sixty AML patients with normal karyotypes were included in this study. Blast cell MPO positivity was assessed in bone marrow smears stained for MPO. Associated genetic lesions (the NPM1, FLT3-ITD, and CEBPA mutations) were studied using nucleotide sequencing. Thirty-two patients were in the MPO-L group, and 28 patients in the MPO-H group. FLT3-ITD was found in 11 patients (18.3%), NPM1 mutations were found in 19 patients (31.7%), and CEBPA mutations were found in 11 patients (18.3%). In patients with CEBPA mutations, the carrying two simultaneous mutations (CEBPA (double-mut)) was associated with high MPO expression, while the mutant NPM1 without FLT3-ITD genotype was not associated with MPO activity. Both higher MPO expression and the CEBPA (double-mut) genotype appeared to be associated with improved overall survival after intensive chemotherapy. Further studies are required to determine the importance of blast MPO activity as a prognostic factor, especially in CEBPA wild-type patients with a normal karyotype. | |||||
書誌情報 |
International Journal of Hematology 巻 94, 号 1, p. 81-89, 発行日 2011-07 |
|||||
出版者 | ||||||
出版者 | Japanese Society of Hematology | |||||
出版者別言語 | ||||||
日本血液学会 | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09255710 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 18653774 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA10797094 | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 21674360 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s12185-011-0883-y | |||||
権利 | ||||||
権利情報 | © The Japanese Society of Hematology 2011 | |||||
権利 | ||||||
権利情報 | The original publication is available at www.springerlink.com | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
関係URI | ||||||
関連名称 | http://hdl.handle.net/10069/30683 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | International Journal of Hematology, 94(1), pp.81-89: 2011 |